Ameriprise
PPH icon

Ameriprise’s VanEck Pharmaceutical ETF PPH Stock Holding History

Ameriprise’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542K Sell
4,961
-173
-3% -$17.9K ﹤0.01% 3638
2026
Q1 		$533K Buy
5,134
+919
+22% +$97.9K ﹤0.01% 3562
2025
Q4 		$435K Buy
4,215
+863
+26% +$84K ﹤0.01% 3676
2025
Q3 		$303K Sell
3,352
-12
-0.4% -$1.05K ﹤0.01% 3797
2025
Q2 		$296K Sell
3,364
-47
-1% -$4.07K ﹤0.01% 3701
2025
Q1 		$311K Sell
3,411
-19,628
-85% -$1.77M ﹤0.01% 3664
2024
Q4 		$1.99M Sell
23,039
-3,806
-14% -$344K ﹤0.01% 2932
2024
Q3 		$2.55M Buy
26,845
+2,446
+10% +$232K ﹤0.01% 2780
2024
Q2 		$2.23M Sell
24,399
-6,729
-22% -$601K ﹤0.01% 2813
2024
Q1 		$2.83M Buy
31,128
+6,705
+27% +$587K ﹤0.01% 2694
2023
Q4 		$1.99M Sell
24,423
-11,852
-33% -$929K ﹤0.01% 2876
2023
Q3 		$2.9M Buy
36,275
+23,812
+191% +$1.92M ﹤0.01% 2641
2023
Q2 		$982K Sell
12,463
-1,435
-10% -$112K ﹤0.01% 3181
2023
Q1 		$1.08M Buy
+13,898
New +$1.07M ﹤0.01% 3113
2017
Q4 		– Sell
-4,567
Closed -$264K – 3715
2017
Q3 		$264K Sell
4,567
-4,304
-49% -$244K ﹤0.01% 3432
2017
Q2 		$524K Buy
8,871
+107
+1% +$6.05K ﹤0.01% 3219
2017
Q1 		$483K Buy
8,764
+928
+12% +$50.3K ﹤0.01% 3187
2016
Q4 		$411K Buy
+7,836
New +$419K ﹤0.01% 3362
2016
Q2 		– Sell
-5,940
Closed -$342K – 3832
2016
Q1 		$342K Buy
5,940
+1,906
+47% +$113K ﹤0.01% 3311
2015
Q4 		$263K Buy
+4,034
New +$261K ﹤0.01% 3547
2014
Q2 		– Sell
-100
Closed -$6K – 5637
2014
Q1 		$6K Hold
100
– – ﹤0.01% 4733
2013
Q4 		$5K Hold
100
– – ﹤0.01% 4622
2013
Q3 		$5K Hold
100
– – ﹤0.01% 5232
2013
Q2 		$5K Buy
+100
New +$4.62K ﹤0.01% 5135

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Ameriprise's PPH Position: Q2 2026 in Review

Ameriprise reduced its VanEck Pharmaceutical ETF (PPH) stake by 3.4% in Q2 2026, selling an estimated $17.9K and leaving 4,961 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #3638.

Ameriprise first reported a position in PPH in Q2 2013 and has held it in 24 quarters since. The position peaked at $2.9M in Q3 2023. 147 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • Ameriprise held 4,961 shares of VanEck Pharmaceutical ETF worth $542K as of Q2 2026.
  • Ameriprise sold 173 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $17.9K.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3638 holding.
  • Ameriprise first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and has held it in 24 quarters since.
  • Ameriprise's VanEck Pharmaceutical ETF position peaked at $2.9M in Q3 2023.
  • 147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.